HYTN Innovations Secures UK Import Permits and Initial Order from 4C Labs

LOS ANGELES- HYTN Innovations Inc., a pharmaceutical company specializing in psychoactive and psychotropic compounds, including cannabis and psilocybin, has received initial orders and import permits from the United Kingdom’s 4C Labs. This development enables HYTN to commence exporting cannabis-based pharmaceuticals to the UK under recently established agreements.

The first shipment, produced in compliance with Good Manufacturing Practices (GMP) standards, signifies HYTN’s commitment to delivering high-quality cannabis products to international markets. CEO Elliot McKerr remarked, “This milestone underscores the strength of our collaboration and signals the shift from a domestic to international cannabis company.”

To facilitate this export, HYTN completed registration with the UK’s National Drugs Control System (NDS), authorizing transactions with UK entities holding domestic controlled drug or drug precursor licenses.

4C Labs, a Canadian-based medical cannabis company, is developing a vertically integrated infrastructure to supply premium medical cannabis products to the UK, EU, and other regulated markets. The partnership with HYTN aims to enhance the availability of cannabis-based pharmaceuticals in these regions.